Abstract
Type 2 diabetes mellitus is an urgent problem of health care. Comparison of the structure of the Rivaroxaban with the structure of a number of experimental drugs, which are Glucokinase activators, revealed the perspectives of its evalua-tion in the drug design for the treatment of type 2 diabetes. In in silico experi-ments, the interaction of Rivaroxaban with glucokinase, which is involved in glu-cose phosphorylation in liver and pancreas cells, has been studied. Using molecu-lar docking methods, complexes of Rivaroxaban with a protein in the allosteric center responsible for the action of glucokinase activators, were generated: the minimum binding energy was found 9.41 kcal/mol. The results obtained in the experiment in silico open the perspectives of design and development of the new effective antidiabetic drugs as well as investigation of the concomitant action of the anticoagulant Rivaroxaban.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
